• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Climb Bio Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    5/14/25 7:05:09 AM ET
    $CLYM
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CLYM alert in real time by email
    8-K
    0001768446false00017684462025-05-142025-05-14

     

     

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

    FORM 8-K

    CURRENT REPORT

    Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported): May 14, 2025

    CLIMB BIO, INC.

    (Exact name of Registrant as Specified in Its Charter)

    Delaware

    001-40708

    83-2273741

    (State or Other Jurisdiction

    of Incorporation)

    (Commission File Number)

    (IRS Employer

    Identification No.)

     

     

     

    20 William Street

    Suite 145

    Wellesley Hills, MA

    02481

    (Address of Principal Executive Offices)

    (Zip Code)

    Registrant’s Telephone Number, Including Area Code: (866) 857-2596

    Not Applicable

    (Former Name or Former Address, if Changed Since Last Report)

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐

    Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

    ☐

    Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

    ☐

    Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

    ☐

    Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class

     

    Trading

    Symbol(s)

     

    Name of each exchange on which registered

     

    Common Stock, par value $0.0001 per share

     

    CLYM

     

    The Nasdaq Stock Market LLC

     (The Nasdaq Global Market)

     

     


     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

    Emerging growth company ☒

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     


     

    Item 2.02. Results of Operations and Financial Condition.

    On May 14, 2025, Climb Bio, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2025. A copy of the press release is attached hereto as Exhibit 99.1 and incorporated by reference herein.

     

    The information in this Item 2.02, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

    Item 9.01. Financial Statements and Exhibits.

    (d) Exhibits.

     

    Exhibit

    Number

    Description

    99.1

    Press release of Climb Bio, Inc., dated May 14, 2025

     104

    Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

     

     

     

    1


     

    SIGNATURES

    Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Climb Bio, Inc.

    Date: May 14, 2025

    By:

    /s/ Aoife Brennan

    Aoife Brennan, M.B., Ch.B.

    President and Chief Executive Officer

     

     

    2


    Get the next $CLYM alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CLYM

    DatePrice TargetRatingAnalyst
    6/6/2025$10.00Outperform
    Oppenheimer
    5/22/2025$7.00Buy
    BTIG Research
    12/2/2024$10.00Outperform
    Leerink Partners
    More analyst ratings

    $CLYM
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Climb Bio Appoints Edgar D. Charles, M.D., MSc as Chief Medical Officer

      Dr. Charles, Accomplished Immunology-Focused Drug Developer, Brings More Than 20 years of Biopharma Leadership, Clinical Development, and Operations Expertise Company Also Hires Cindy J. Driscoll, MBA, Financial Executive with Over Two Decades of Experience Guiding Biotechnology Companies, as Senior Vice President, Finance WELLESLEY HILLS, Mass., June 18, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced the appointments of Edgar D. Charles, M.D., MSc as its Chief Medical Officer (CMO) and Cindy J. Driscoll, MBA as Senior Vice President, Finance. "The expansi

      6/18/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

      WELLESLEY HILLS, Mass., May 19, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today announced that the Company has granted an inducement equity award to a new employee, pursuant to the Company's 2025 Inducement Plan, as an inducement material to the new employee entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4). The inducement equity award was granted to one new employee on May 19, 2025, and consisted of a non-statutory stock option to purchase up to an aggregate of 120,000 shares of common stock of the Company. The option has an ex

      5/19/25 4:34:52 PM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Climb Bio Reports First Quarter 2025 Financial Results and Provides Business Updates

      Clinical Trials of Budoprutug in Primary Membranous Nephropathy (pMN), Immune Thrombocytopenia (ITP), and Systemic Lupus Erythematosus (SLE) on Track to Initiate in 2025 CLYM116 Progressing Towards Anticipated IND or CTA Submission in Second Half 2025 Appointed Kim Cobleigh Drapkin, CPA, and Bo Cumbo as Independent Directors and Perrin Wilson, Ph.D., as Chief Business Officer Strong Financial Position, with Cash Runway Expected Through 2027 WELLESLEY HILLS, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Climb Bio, Inc. (NASDAQ:CLYM), a clinical stage biotechnology company developing therapeutics for patients with immune-mediated diseases, today reported financial results for the first quarte

      5/14/25 7:00:00 AM ET
      $CLYM
      Biotechnology: Pharmaceutical Preparations
      Health Care